Neuroendocrine System Regulatory Mechanisms: Acute Coronary Syndrome and Stress Hyperglycaemia

The aim of reviewing the neuroendocrine–humoral response in acute coronary syndrome (ACS) is based on the fact that beyond the distinctive thrombotic event that defines acute occlusion of a coronary artery, generically referred to as a plaque accident, it is not an isolated event.

ISCP Guest Editorial: Cardiovascular Disease Prevention in Diabetes

Type 2 diabetes is a major risk factor for the development of cardiovascular disease (CVD) such as MI, and cerebrovascular incidents such as stroke. A substantial body of evidence has indicated that the proper management of blood glucose in people with diabetes can inhibit the progression of microvascular disease such as retinopathy and nephropathy.

Cardiovascular Implications of Sphingomyelin Presence in Biological Membranes

Sphingolipids are one of the major categories of lipids and beyond their role as structural membrane components they have important functions as signalling molecules in a wide array of biological processes. They are composed of two key lipid building blocks – long-chain bases (usually sphingosine or 1,3-dihydroxy-2-amino-4-octadecene) and fatty acids – and use a glycerol-based backbone to which acyl chains are attached.1,2

Diabetes Drugs and Cardiovascular Event Reduction: A Paradigm Shift

Diabetes mellitus is one of the most common chronic diseases, affecting >30 million people in the US and 422 million worldwide.1,2 Alarmingly, both the incidence and prevalence of type 2 diabetes have doubled in the US since 1990.3 This is driven by an aging population, obesity, physical inactivity, and prolonged survival in those with diabetes, among other factors.

Influence of Race in the Association of Diabetes and Heart Failure

Heart failure (HF) is a global public health problem, affecting an estimated 26 million people worldwide and resulting in more than 1 million hospitalizations annually in the US and Europe.1 This HF pandemic is also evident in Asia and other parts of the world.2–4 Although the outcomes for HF patients have improved with the discovery of multiple evidence-based drug and device therapies, hospitalized HF patients continue to experience unacceptably high mortality and readmission rates t

Natriuretic Peptide-based Screening and Prevention of Heart Failure

Increasingly biomarkers are of interest in cardiovascular disease (CVD) for risk stratification. In particular, natriuretic peptides (NPs), which were originally used for the diagnosis of heart failure, are now finding a role in identifying those most at risk of heart failure and other cardiovascular (CV) disorders. Their ability to be measured rapidly through blood tests makes their widespread use more practical.